Holen Sie sich die Stockscreener-App
7.04
0.98%
-0.07
Handel nachbörslich:
7.01
-0.03
-0.43%
Schlusskurs vom Vortag:
$7.11
Offen:
$6.9
24-Stunden-Volumen:
983.83K
Relative Volume:
1.55
Marktkapitalisierung:
$524.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-12.57
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
+2.47%
1M Leistung:
+20.75%
6M Leistung:
+132.34%
1J Leistung:
+3.68%
1-Tages-Spanne:
$6.81
$7.25
1-Wochen-Bereich:
$6.39
$7.51
52-Wochen-Spanne:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
7.04 | 529.79M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Will Corvus Pharmaceuticals Inc. stock go up soonQuarterly Market Review & Technical Confirmation Alerts - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackWatch List & Free Expert Verified Stock Movement Alerts - newser.com
Should you hold or exit Corvus Pharmaceuticals Inc. nowPortfolio Update Report & Daily Profit Focused Stock Screening - newser.com
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.July 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Barclays Initiates Corvus Pharmaceuticals at Overweight With $16 Price Target - MarketScreener
Barclays Initiates Coverage on CRVS with Overweight Rating | CRV - GuruFocus
Barclays initiates Corvus Pharmaceuticals stock with Overweight rating - Investing.com
Corvus Pharmaceuticals Inc.’s volatility index tracking explainedShort Setup & Safe Entry Momentum Stock Tips - newser.com
What analysts say about Corvus Pharmaceuticals Inc stockInsider Trading Activity & Free Lightning Fast Capital Gains - earlytimes.in
Weiss Ratings Reaffirms "Sell (D-)" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Detecting support and resistance levels for Corvus Pharmaceuticals Inc.July 2025 Momentum & Verified Momentum Watchlists - newser.com
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $672,000 in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Has Corvus Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-03 06:35:03 - newser.com
Measuring Corvus Pharmaceuticals Inc.’s beta against major indicesEarnings Miss & Community Verified Trade Signals - newser.com
Chart based exit strategy for Corvus Pharmaceuticals Inc.July 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com
Candlestick signals on Corvus Pharmaceuticals Inc. stock todayWall Street Watch & Daily Stock Trend Watchlist - newser.com
Corvus Pharmaceuticals appoints David Moore to board of directors - Investing.com
Corvus Pharmaceuticals Appoints David Moore To Board Of Directors - TradingView
Novo Nordisk EVP David Moore Joins Corvus Board to Advance ITK Inhibitor Platform and Commercial Strategy - Stock Titan
Published on: 2025-10-01 07:08:07 - newser.com
What drives Corvus Pharmaceuticals Inc stock priceStock Rotation Strategies & Low Risk Capital Appreciation - earlytimes.in
Is Corvus Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Tap Into the Fastest-Growing Companies - Early Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6.1%Should You Buy? - MarketBeat
Are Investors Undervaluing Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) By 37%? - 富途牛牛
While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st
Is Corvus Pharmaceuticals Inc. trending in predictive chart modelsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
What candlestick patterns are forming on Corvus Pharmaceuticals Inc.Weekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a reversal patternMarket Trend Report & Reliable Intraday Trade Plans - newser.com
How to integrate Corvus Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Moving Averages: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2025 Performance Recap & Risk Controlled Daily Trade Plans - خودرو بانک
Using data models to predict Corvus Pharmaceuticals Inc. stock movement2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
How to manage a losing position in Corvus Pharmaceuticals Inc.Quarterly Trade Summary & Fast Entry High Yield Tips - newser.com
Will Corvus Pharmaceuticals Inc stock hit new highs in YEAR2025 Growth vs Value & Accurate Technical Buy Alerts - khodrobank.com
Layoff Watch: Is Corvus Pharmaceuticals Inc undervalued by DCF analysisMarket Performance Report & Low Drawdown Investment Ideas - khodrobank.com
Visual analytics tools that track Corvus Pharmaceuticals Inc. performanceQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):